Boston Scientific Corporation (NYSE:BSX) Sees Large Increase in Short Interest

Boston Scientific Corporation (NYSE:BSX) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 48,173,758 shares, a growth of 74.4% from the August 15th total of 27,617,554 shares. Approximately 3.3% of the company’s stock are short sold. Based on an average daily volume of 21,036,931 shares, the short-interest ratio is currently 2.3 days.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Raymond James Financial reiterated an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. TD Cowen reiterated a “buy” rating and set a $56.00 price objective on shares of Boston Scientific in a research note on Tuesday, August 25th. Truist Financial cut their target price on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Royal Bank Of Canada lowered their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.46.

Boston Scientific Stock Performance

NYSE BSX traded up $0.10 on Wednesday, hitting $43.97. The stock had a trading volume of 28,465,830 shares, compared to its average volume of 18,642,408. The company’s 50-day moving average is $46.97 and its two-hundred day moving average is $54.10. Boston Scientific has a one year low of $42.20 and a one year high of $105.65. The stock has a market cap of $63.72 billion, a price-to-earnings ratio of 17.80, a P/E/G ratio of 1.04 and a beta of 0.57. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts expect that Boston Scientific will post 3.29 earnings per share for the current year.

Insider Activity

In related news, Director Edward Ludwig bought 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael Mahoney purchased 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. State Street Corp grew its position in Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after buying an additional 920,495 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Boston Scientific during the 2nd quarter worth about $5,534,781,000. Capital World Investors raised its position in shares of Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares in the last quarter. Norges Bank acquired a new stake in shares of Boston Scientific in the 4th quarter worth approximately $2,199,395,000. Finally, Primecap Management Co. CA bought a new position in shares of Boston Scientific in the second quarter valued at approximately $2,156,233,000. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.